Todos Med Ltd (TOMDF)

[JoeForkeyBolo]

Gerald Commissiong on Twitter

New management will make sense at the right time. It’s not that time yet. I have no interest in staying in penny land and no interest in another Amarantus decline. With that said, Todos is extremely different than Amarantus in many ways and these differences will underlie a /1

— Gerald Commissiong (@G_Commish) September 26, 2020

Replying to @Jay70272671

New management will make sense at the right time. It’s not that time yet. I have no interest in staying in penny land and no interest in another Amarantus decline. With that said, Todos is extremely different than Amarantus in many ways and these differences will underlie a very different outcome. Todos is generating revenue, which Amarantus never did. Todos has forecasted revenue growth that far far exceeds our market cap. Most of the Todos funders are high net worth. Todos has significantly less debt. Todos will be profitable very soon. Todos is operating in the #1 most needed area for new emerging companies on the planet as it relates to COVID testing and we have a neutraceutical program that will start generating cash flow for us, not a years long Pharma program. Todos’ programs are very synergistic. I also learned quite a bit from the Amarantus experience and am leveraging that to make much better decisions for Todos. Being an OTC penny stock comes with unique challenges we are much much better equipped to deal with them at Todos.

And let’s not forget the mobile labs. That is a complete game changer.